Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans.
Patients with edematous diseases are generally treated with diuretics, but frequently present with hyponatremia associated with impaired water excretion. This study investigated the combined effects of vasopressin V2 receptor antagonist OPC-31260, an aquaretic, and furosemide, a saluretic, on free water excretion and serum sodium concentration (PNa). The study was planned as an open-label, 4-period, 4-treatment, crossover study in 12 healthy subjects using single doses of placebo, furosemide 20 mg (F), OPC-31260 30 mg (O), and furosemide 20 mg plus OPC-31260 30 mg (O+F). OPC-31260 co-administered with furosemide induced an increase in PNa and serum osmolality (F: 281.6 +/- 0.7, O+F: 284.9 +/- 0.7 mOsm/kgH2O) as a result of an additive increase in maximal urine volume (F: 7.7 +/- 1.9, O: 6.8 4 0.5, O+F: 13.2 +/- 1.4 ml/min) with increased electrolyte-free water excretion (F: 0.35 +/- 0.15, O: 5.3 4 0.5, O+F: 4.8 +/- 0.5 ml/min) while maintaining sodium excretion (F: 731 +/- 110, O+F: 1,064 +/- 149 microEq/min). It was suggested that by the co-administration, the resulting decreased generation of free water in Henle's loop was canceled out by a decrease in back--diffusion of free water across the collecting ducts. The co-administration may be particularly effective in treating edema and hyponatremia in edematous diseases.